108 related articles for article (PubMed ID: 12037506)
1. [Rosiglitazone: a clinical development focused on cardio-vascular prevention].
Valensi P
Ann Endocrinol (Paris); 2002 Apr; 63(2 Pt 2):1S35-40. PubMed ID: 12037506
[TBL] [Abstract][Full Text] [Related]
2. Rosiglitazone: potential beneficial impact on cardiovascular disease.
Viberti GC
Int J Clin Pract; 2003 Mar; 57(2):128-34. PubMed ID: 12661797
[TBL] [Abstract][Full Text] [Related]
3. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
Yener S; Comlekci A; Akinci B; Demir T; Yuksel F; Ozcan MA; Bayraktar F; Yesil S
Med Princ Pract; 2009; 18(4):266-71. PubMed ID: 19494532
[TBL] [Abstract][Full Text] [Related]
4. Rosiglitazone reduces blood pressure and urinary albumin excretion in type 2 diabetes: G Bakris et al.
Grossman E
J Hum Hypertens; 2003 Jan; 17(1):5-6. PubMed ID: 12571610
[No Abstract] [Full Text] [Related]
5. Cardiovascular effects of troglitazone.
Umland EM; Romanelli AM
Ann Pharmacother; 1999 Feb; 33(2):229-32. PubMed ID: 10084419
[No Abstract] [Full Text] [Related]
6. Rosiglitazone reduces urinary albumin excretion in type II diabetes.
Bakris G; Viberti G; Weston WM; Heise M; Porter LE; Freed MI
J Hum Hypertens; 2003 Jan; 17(1):7-12. PubMed ID: 12571611
[TBL] [Abstract][Full Text] [Related]
7. [Cardiovascular effects of rosiglitazone].
Le Feuvre C
Presse Med; 2004 Jun; 33(11):735-45. PubMed ID: 15257231
[TBL] [Abstract][Full Text] [Related]
8. Metabolic and additional vascular effects of thiazolidinediones.
Martens FM; Visseren FL; Lemay J; de Koning EJ; Rabelink TJ
Drugs; 2002; 62(10):1463-80. PubMed ID: 12093315
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions.
Roberts AW; Thomas A; Rees A; Evans M
Curr Opin Lipidol; 2003 Dec; 14(6):567-73. PubMed ID: 14624133
[TBL] [Abstract][Full Text] [Related]
10. Adiponectin mediates the suppressive effect of rosiglitazone on plasminogen activator inhibitor-1 production.
Hoo RL; Chow WS; Yau MH; Xu A; Tso AW; Tse HF; Fong CH; Tam S; Chan L; Lam KS
Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2777-82. PubMed ID: 17932317
[TBL] [Abstract][Full Text] [Related]
11. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.
Irons BK; Greene RS; Mazzolini TA; Edwards KL; Sleeper RB
Pharmacotherapy; 2006 Feb; 26(2):168-81. PubMed ID: 16466323
[TBL] [Abstract][Full Text] [Related]
12. Possible vascular-protective effects of antidiabetic agents such as the thiazolidinediones (TZDs).
Goldstein BJ
Clin Ther; 2002 Aug; 24(8):1358-60; author reply 1360-2. PubMed ID: 12240785
[No Abstract] [Full Text] [Related]
13. Cardiovascular risk reduction with pioglitazone.
Cardiovasc J S Afr; 2002; 13(4):218. PubMed ID: 12402932
[No Abstract] [Full Text] [Related]
14. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease.
Marx N; Froehlich J; Siam L; Ittner J; Wierse G; Schmidt A; Scharnagl H; Hombach V; Koenig W
Arterioscler Thromb Vasc Biol; 2003 Feb; 23(2):283-8. PubMed ID: 12588772
[TBL] [Abstract][Full Text] [Related]
15. Rationale for and role of thiazolidinediones in type 2 diabetes mellitus.
Lebovitz HE
Am J Cardiol; 2002 Sep; 90(5A):34G-41G. PubMed ID: 12231077
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular disease and benefits of thiazolidinediones.
Braunstein S
Postgrad Med; 2003 May; Spec No():45-52. PubMed ID: 12785131
[TBL] [Abstract][Full Text] [Related]
17. [Heart, diabetes and glitazones].
Le Feuvre C
Ann Endocrinol (Paris); 2004 Feb; 65(1 Suppl):S26-35. PubMed ID: 15163921
[TBL] [Abstract][Full Text] [Related]
18. Rosiglitazone approved for treatment of type 2 diabetes.
Miller JL
Am J Health Syst Pharm; 1999 Jul; 56(13):1292, 1294. PubMed ID: 10683120
[No Abstract] [Full Text] [Related]
19. Guidance on rosiglitazone for type 2 diabetes mellitus.
Matthews DR
Lancet; 2001 Feb; 357(9254):481. PubMed ID: 11273100
[No Abstract] [Full Text] [Related]
20. Study to investigate cognitive function in type 2 diabetes.
Cockey CD
AWHONN Lifelines; 2002; 6(1):16-7. PubMed ID: 11913196
[No Abstract] [Full Text] [Related]
[Next] [New Search]
